Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00062478
Status:
COMPLETED
Last Update Posted:
2020-03-12
First Post:
2003-06-06
Brief Title:
Study of Karenitecin BNP1350 in Patients With Brain Tumors
Sponsor:
BioNumerik Pharmaceuticals Inc
Organization:
BioNumerik Pharmaceuticals Inc
Study Overview
Official Title:
Phase 2 Treatment of Adults With Primary Malignant Glioma With Karenitecin
Status:
COMPLETED
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate safety and efficacy ofKarenitecin BNP1350 as a treatment of adults with brain tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None